Table 2.

Summary of efficacy and safety results (including important subgroup analyses).

Parameter	Rabeprazole 10 mg (d)	Esomeprazole 20 mg (d)	P	Result
Primary efficacy variables
Time to 24-h symptom-free interval-HB	8.5 d	9 d	0.265	NS
Time to 24-h symptom-free interval-RG	6.0 d	7.5 d	0.405	NS
Secondary efficacy variables
Time to 48-h symptom-free interval-HB	9.5 d	8.5 d	0.373	NS
Time to 48-h symptom-free interval-RG	8.5 d	11 d	0.271	NS
W1-W4-satisfactory relief DT or NT-HB			>0.05	NS
W1-W4-satisfactory relief DT or NT-RG			>0.05	NS
W1-W4-satisfactory relief DT-HB & RG4			0.0454	Rabeprazole superior4
W1-W4-complete relief DT or NT-HB			>0.05	NS
W1-W4-complete relief DT or NT-RG			>0.05	NS
W1-W4-belching	-0.41	-0.42	0.631	NS
W1-W4-early satiety	-0.26	-0.32	0.178	NS
W1-W4-bloating	-0.46	-0.54	0.608	NS
W1-W4-nausea	-0.23	-0.27	0.319	NS
W1-W4-vomiting	-0.34	-0.21	0.808	NS
Symptom severity score-D1-5-DT HB	P<0.05 (D2-5)1	P<0.05 (D3-5)1		NS2
Symptom severity score-D1-5-NT HB	P<0.05 (D2-5)1	NS1		NS3
Symptom severity score-D1-5-DT RG	P<0.05 (D1-5)1	P<0.05 (D1-5)1		NS
Symptom severity score-D1-5-NT RG	P<0.05 (D5 only)1	P<0.05 (D2 only)1		NS
Patient’s global evaluation (%)	96.4	87.9	0.823	NS
Antacid use-weekly average	0.15	0.16	0.887	NS
Antacid use-% antacid free	85.7	84.9	0.848	NS
Safety
Adverse events	22	18.2	>0.05	NS

HB-heartburn; RG-regurgitation; DT-day-time; NT-night-time; W1-wk 1; w4-wk 4;

¹Compared to baseline;

²Rabeprazole statistically superior compared to baseline/pre-treatment from d 2 to 5 and esomeprazole statistically superior compared to baseline/pre-treatment from d 3 to 5;

³Rabeprazole statistically superior compared to baseline/pre-treatment from d 2 to 5 and esomeprazole not statistically superior compared to baseline/pre-treatment from d 1 to 5;

⁴Subgroup analysis.